Underexpression of specific interferon genes is associated with poor prognosis of melanoma

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Zainulabadeen, Aamir ^a,b   Yao, Philip ^a,c   Zare, Habil ^a  

^a Texas State University   (United States)

^b Princeton University   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; RETINOIC ACID INDUCIBLE PROTEIN I; STAT1 PROTEIN; INTERFERON;

ARTICLE; AURKB GENE; CANCER PROGNOSIS; CCNE1 GENE; CDCA8 GENE; CDK4 GENE; CENPO GENE; CONTROLLED STUDY; DDX58 GENE; EIF2AK2 GENE; GBP3 GENE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GINS2 GENE; H2AFZ GENE; HERC5 GENE; HIGH RISK POPULATION; HUMAN; IFIT1 GENE; IFIT2 GENE; IFIT3 GENE; IN VIVO STUDY; LIG1 GENE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MELANOMA; OAS1 GENE; OAS2 GENE; OAS3 GENE; PKMYT1 GENE; PLK1 GENE; PROBABILITY; PSMB8 GENE; PTTG1 GENE; SKA1 GENE; SP100 GENE; STAT1 GENE; SURVIVAL ANALYSIS; SURVIVAL RATE; TUBA1B GENE; TUBA1C GENE; TYMS GENE; UBE2L6 GENE; UNDEREXPRESSION; USP18 GENE; XAF1 GENE; GENE EXPRESSION PROFILING; GENETICS; PATHOLOGY; PROGNOSIS; SKIN TUMOR;

GENE EXPRESSION PROFILING; HUMANS; INTERFERONS; MELANOMA; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 85010383206     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0170025     Document Type: Article

References (102)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015;65(1):5-29.
2. Balch CM, Gershenwald JE, Soong Sj, Thompson JF, Ding S, Byrd DR, et al. Multivariate analysis of prognostic factors among 2, 313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. Journal of Clinical Oncology. 2010;28(14):2452-2459. doi:10.1200/JCO.2009.27.1627 PMID: 20368546
3. Balch CM, Gershenwald JE, Soong Sj, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. Journal of clinical oncology. 2009;27(36):6199-6206. doi:10.1200/JCO.2009.23.4799 PMID: 19917835
4. Gerami P, Cook RW, Wilkinson J, Russell MC, Dhillon N, Amaria RN, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clinical Cancer Research. 2015;21(1):175-183. doi:10.1158/1078-0432. CCR-13-3316 PMID: 25564571
5. Sondak VK, Messina JL. Prediction is Difficult, Especially About the Future: Clinical Prognostic Tools in Melanoma. Annals of surgical oncology. 2016; p. 1-3.
6. Gimotty PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. Journal of Clinical Oncology. 2007;25(9):1129-1134. doi:10.1200/JCO.2006.08.1463 PMID: 17369575
7. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. New England Journal of Medicine. 2006;355(13):1307-1317. doi:10.1056/NEJMoa060992 PMID: 17005948
8. Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, et al. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and its Expression Associates with Favorable Survival for Stage III Melanoma. Clinical Cancer Research. 2016; p. clincanres-2226. doi:10.1158/1078-0432. CCR-15-2226 PMID: 26783288
9. Kimbrough CW, Egger ME, McMasters KM, Stromberg AJ, Martin RC, Philips P, et al. Molecular Staging of Sentinel Lymph Nodes Identifies Melanoma Patients at Increased Risk of Nodal Recurrence. Journal of the American College of Surgeons. 2016;222(4):357-363. doi:10.1016/j.jamcollsurg.2015.12.042 PMID: 26875070
10. Weiss SA, Hanniford D, Hernando E, Osman I. Revisiting determinants of prognosis in cutaneous melanoma. Cancer. 2015;121(23):4108-4123. doi:10.1002/cncr.29634 PMID: 26308244
11. Francis P, Namløs HM, Mü ller C, Edén P, Fernebro J, Berner JM, et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC genomics. 2007;8(1):1. doi:10.1186/1471-2164-8-73
12. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine. 2004;351(27):2817-2826. doi:10.1056/NEJMoa041588 PMID: 15591335
13. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, et al. A multigene predictor of outcome in glioblastoma. Neuro-oncology. 2009; p. nop007.
14. Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Richards WG, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. Journal of the National Cancer Institute. 2003;95(8):598-605. doi:10.1093/jnci/95.8.598 PMID: 12697852
15. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer research. 2004;64(20):7205-7209. doi:10.1158/0008-5472. CAN-04-1750 PMID: 15492234
16. Lee CY, Gerami P. Molecular techniques for predicting behaviour in melanocytic neoplasms. Pathology. 2016;48(2):142-146. doi:10.1016/j.pathol.2015.12.004 PMID: 27020386
17. March J, Hand M, Truong A, Grossman D. Practical application of new technologies for melanoma diagnosis: Part II. Molecular approaches. Journal of the American Academy of Dermatology. 2015;72(6):943-958. doi:10.1016/j.jaad.2015.02.1138 PMID: 25980999
18. Ji AL, Bichakjian CK, Swetter SM. Molecular Profiling in Cutaneous Melanoma. Journal of the National Comprehensive Cancer Network. 2016;14(4):475-480. PMID: 27059194
19. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. The Journal of Molecular Diagnostics. 2010;12(4):461-468. doi:10.2353/jmoldx.2010.090220 PMID: 20413675
20. Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119(8):1596-1603. doi:10.1016/j.ophtha.2012.02.017 PMID: 22521086
21. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clinical cancer research. 2007;13(3):806-815. doi:10.1158/1078-0432. CCR-06-1820 PMID: 17289871
22. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406(6795):536-540. doi:10.1038/35020115 PMID: 10952317
23. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, et al. The gene expression signatures of melanoma progression. Proceedings of the National Academy of Sciences. 2005;102(17):6092-6097. doi:10.1073/pnas.0501564102
24. Scatolini M, Grand MM, Grosso E, Venesio T, Pisacane A, Balsamo A, et al. Altered molecular pathways in melanocytic lesions. International Journal of Cancer. 2010;126(8):1869-1881. PMID: 19795447
25. Smith AP, Hoek K, Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer biology & therapy. 2005;4(9):1018-1029. doi:10.4161/cbt.4.9.2165
26. Weeraratna AT, Becker D, Carr KM, Duray PH, Rosenblatt KP, Yang S, et al. Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene. 2004;23(12):2264-2274. doi:10.1038/sj.onc.1207337 PMID: 14755246
27. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. Journal of the National Cancer Institute. 2006;98(7):472-482. doi:10.1093/jnci/djj103 PMID: 16595783
28. Gene Ontology Consortium. Gene ontology: tool for the unification of biology. Nature Genetics. 2000;25(1):25-9. doi:10.1038/75556 PMID: 10802651
29. Gerami P, Cook RW, Russell MC, Wilkinson J, Amaria RN, Gonzalez R, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. Journal of the American Academy of Dermatology. 2015;72(5):780-785. doi:10.1016/j.jaad.2015.01. 009 PMID: 25748297
30. Berger AC, Davidson RS, Poitras JK, Chabra I, Hope R, Brackeen A, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Current medical research and opinion. 2016; (just-accepted): 1-23.
31. Cassarino DS, Lewine N, Cole D, Wade B, Gustavsen G. Budget impact analysis of a novel gene expression assay for the diagnosis of malignant melanoma. Journal of medical economics. 2014;17(11):782-791. doi:10.3111/13696998.2014.950421 PMID: 25170544
32. Mahar AL, Compton C, Halabi S, Hess KR, Gershenwald JE, Scolyer RA, et al. Critical assessment of clinical prognostic tools in melanoma. Annals of surgical oncology. 2016; p. 1-9. doi:10.1245/s10434-016-5212-5 PMID: 27052645
33. Network CGA, et al. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681-1696. doi:10.1016/j.cell.2015.05.044
34. Zare H, et al. Pigengene: Computing and using eigengenes. Bioconductor; 2016. Available from: https://bioconductor.org/packages/devel/bioc/html/Pigengene.html.
35. Talantov D, Mazumder A, Jack XY, Briggs T, Jiang Y, Backus J, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clinical Cancer Research. 2005;11(20):7234-7242. doi:10.1158/1078-0432. CCR-05-0683 PMID: 16243793
36. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC medical genomics. 2008;1(1):1. doi:10.1186/1755-8794-1-13
37. Brunner G, Reitz M, Schwipper V, Tilkorn H, Lippold A, Biess B, et al. Increased expression of the tumor suppressor PLZF is a continuous predictor of long-term survival in malignant melanoma patients. Cancer biotherapy & radiopharmaceuticals. 2008;23(4):451-460. doi:10.1089/cbr.2008. 0473
38. Brunner G, Reitz M, Heinecke A, Lippold A, Berking C, Suter L, et al. A nine-gene signature predicting clinical outcome in cutaneous melanoma. Journal of cancer research and clinical oncology. 2013;139(2):249-258. doi:10.1007/s00432-012-1322-z PMID: 23052696
39. Nsengimana J, Laye J, Filia A, Walker C, Jewell R, Van den Oord JJ, et al. Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort. Oncotarget. 2015;6(13):11683. doi:10.18632/oncotarget.3549 PMID: 25871393
40. Cirenajwis H, Ekedahl H, Lauss M, Harbst K, Carneiro A, Enoksson J, et al. Molecular stratification of metastatic melanoma using gene expression profiling: prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget. 2015;. doi:10.18632/oncotarget.3655
41. Wan YW, Allen GI, Liu Z. TCGA2STAT: simple TCGA data access for integrated statistical analysis in R. Bioinformatics. 2015; p. btv677. PMID: 26568634
42. Patro R, Mount SM, Kingsford C. Sailfish enables alignment-free isoform quantification from RNA-seq reads using lightweight algorithms. Nature biotechnology. 2014;32(5):462-464. doi:10.1038/nbt. 2862 PMID: 24752080
43. Clark WH, Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. Journal of the National Cancer Institute. 1989;81(24):1893-1904. doi:10.1093/jnci/81.24.1893 PMID: 2593166
44. Daniel WW. Spearman rank correlation coefficient. Applied nonparametric statistics, 2nd ed PWSKent, Boston. 1990; p. 358-365.
45. Kumari S, Nie J, Chen HS, Ma H, Stewart R, Li X, et al. Evaluation of gene association methods for coexpression network construction and biological knowledge discovery. PloS one. 2012;7(11):e50411. doi:10.1371/journal.pone.0050411 PMID: 23226279
46. Mukaka M. A guide to appropriate use of Correlation coefficient in medical research. Malawi Medical Journal. 2012;24(3):69-71. PMID: 23638278
47. Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell. 2013;153(3):707-720. doi:10.1016/j.cell.2013.03.030 PMID: 23622250
48. Bostick PJ, Morton DL, Turner RR, Huynh KT, Wang HJ, Elashoff R, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. Journal of clinical oncology. 1999;17(10):3238-3244. PMID: 10506625
49. Essner R, Lee JH, Wanek LA, Itakura H, Morton DL. Contemporary surgical treatment of advancedstage melanoma. Archives of surgery. 2004;139(9):961-967. doi:10.1001/archsurg.139.9.961 PMID: 15381613
50. Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Annals of Surgical Oncology. 2002;9(7):637-645. doi:10.1007/BF02574479 PMID: 12167577
51. Karjalainen JM, Kellokoski JK, Eskelinen MJ, Alhava EM, Kosma VM. Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. Journal of clinical oncology. 1998;16(11):3584-3591. PMID: 9817279
52. Kolesnikov N, Hastings E, Keays M, Melnichuk O, Tang YA, Williams E, et al. ArrayExpress update x2014;simplifying data submissions. Nucleic acids research. 2014; p. gku1057. doi:10.1093/nar/gku1057 PMID: 25361974
53. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic acids research. 2013;41(D1):D991-D995. doi:10. 1093/nar/gks1193 PMID: 23193258
54. Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and Bio-Conductor. Bioinformatics. 2007;23(14):1846-1847. doi:10.1093/bioinformatics/btm254 PMID: 17496320
55. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC bioinformatics. 2008;9(1):559. doi:10.1186/1471-2105-9-559 PMID: 19114008
56. Jolliffe I. Principal component analysis. Wiley Online Library; 2002.
57. Oldham MC, Horvath S, Geschwind DH. Conservation and evolution of gene coexpression networks in human and chimpanzee brains. Proceedings of the National Academy of Sciences. 2006;103(47):17973-17978. doi:10.1073/pnas.0605938103
58. Simon N, Friedman J, Hastie T, Tibshirani R, et al. Regularization paths for Cox's proportional hazards model via coordinate descent. Journal of statistical software. 2011;39(5):1-13. doi:10.18637/jss. v039.i05 PMID: 27065756
59. Cox DR. Regression models and life-tables. In: Breakthroughs in statistics. Springer; 1992. p. 527-541.
60. Gui J, Li H. Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data. Bioinformatics. 2005;21(13):3001-3008. doi:10.1093/bioinformatics/bti422 PMID: 15814556
61. Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society Series B (Methodological). 1996; p. 267-288.
62. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. vol. 360. John Wiley & Sons; 2011.
63. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. Springer Science & Business Media; 2000.
64. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American statistical association. 1958;53(282):457-481. doi:10.1080/01621459.1958.10501452
65. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies. J natl cancer inst. 1959;22(4):719-748. PMID: 13655060
66. Breuer K, Foroushani AK, Laird MR, Chen C, Sribnaia A, Lo R, et al. InnateDB: systems biology of innate immunity and beyond-recent updates and continuing curation. Nucleic acids research. 2012; p. gks1147. doi:10.1093/nar/gks1147 PMID: 23180781
67. Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, et al. The Reactome pathway knowledgebase. Nucleic acids research. 2014;42(D1):D472-D477. doi:10.1093/nar/gkt1102 PMID: 24243840
68. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nature Reviews Cancer. 2006;6(5):369-381. doi:10.1038/nrc1881 PMID: 16633365
69. Wang L, Hurley DG, Watkins W, Araki H, Tamada Y, Muthukaruppan A, et al. Cell cycle gene networks are associated with melanoma prognosis. PloS one. 2012;7(4):e34247. doi:10.1371/journal. pone.0034247 PMID: 22536322
70. Mi H, Poudel S, Muruganujan A, Casagrande JT, Thomas PD. PANTHER version 10: expanded protein families and functions, and analysis tools. Nucleic acids research. 2016;44(D1):D336-D342. doi:10.1093/nar/gkv1194 PMID: 26578592
71. Jaccard P. Etude comparative de la distribution florale dans une portion des Alpes et du Jura. Impr. Corbaz; 1901.
72. Tanimoto TT. Elementary mathematical theory of classification and prediction. 1958;.
73. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer chemotherapy reports Part 1. 1966;50(3):163-170. PMID: 5910392
74. Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, et al. Dissection of Immune Gene Networks in Primary Melanoma Tumors Critical for Antitumor Surveillance of Patients with Stage II-III Resectable Disease. Journal of Investigative Dermatology. 2014;134(8):2202-2211. doi:10.1038/jid.2014.85 PMID: 24522433
75. Deivendran S, Marzook KH, Pillai MR. The role of inflammation in cervical cancer. In: Inflammation and Cancer. Springer; 2014. p. 377-399.
76. Scaruffi P, Morandi F, Gallo F, Stigliani S, Parodi S, Moretti S, et al. Bone marrow of neuroblastoma patients shows downregulation of CXCL12 expression and presence of IFN signature. Pediatric blood & cancer. 2012;59(1):44-51. doi:10.1002/pbc.23339
77. Rautela J, Baschuk N, Jayatilleke K, Hertzog P, Parker B. S-20: Exploiting the type-1 interferon pathway as a biomarker and therapeutic target for metastatic cancer. Cytokine. 2014;70(1):25. doi:10. 1016/j.cyto.2014.07.240
78. Lu S, Pardini B, Cheng B, Naccarati A, Huhn S, Vymetalkova V, et al. Single nucleotide polymorphisms within interferon signaling pathway genes are associated with colorectal cancer susceptibility and survival. PloS one. 2014;9(10):e111061. doi:10.1371/journal.pone.0111061 PMID: 25350395
79. Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Pan X, et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget. 2013;4(11):2067-2079. doi:10. 18632/oncotarget.1542 PMID: 24162015
80. Moerdyk-Schauwecker M, Shah NR, Murphy AM, Hastie E, Mukherjee P, Grdzelishvili VZ. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology. 2013;436(1):221-234. doi:10.1016/j.virol.2012.11.014 PMID: 23246628
81. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med. 2007;4(5):e176. doi:10.1371/journal.pmed.0040176 PMID: 17488182
82. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer research. 2004;64(15):5270-5282. doi:10.1158/0008-5472. CAN-04-0731 PMID: 15289333
83. Kim SH, Gunnery S, Choe JK, Mathews MB. Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR. Oncogene. 2002;21(57):8741-8748. doi:10.1038/sj.onc.1205987 PMID: 12483527
84. Litvin O, Schwartz S, Wan Z, Schild T, Rocco M, Oh NL, et al. Interferon α/β enhances the cytotoxic response of MEK inhibition in melanoma. Molecular cell. 2015;57(5):784-796. doi:10.1016/j.molcel.2014.12.030 PMID: 25684207
85. Belmar-Lopez C, Mancheno-Corvo P, Saornil MA, Baril P, Vassaux G, Quintanilla M, et al. Uveal vs. cutaneous melanoma. Origins and causes of the differences. Clinical and Translational Oncology. 2008;10(3):137-142. doi:10.1007/s12094-008-0170-4 PMID: 18321815
86. Somasundaram R, Villanueva J, Herlyn M. Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Advances in pharmacology (San Diego, Calif). 2012;65:335. doi:10.1016/B978-0-12-397927-8.00011-7
87. Anaka M, Hudson C, Lo PH, Do H, Caballero OL, Davis ID, et al. Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors. BMC medical genomics. 2013;6(1):1. doi:10.1186/1755-8794-6-40
88. Sun Xx, Yu Q. Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacologica Sinica. 2015;36(10):1219-1227. doi:10.1038/aps.2015.92 PMID: 26388155
89. Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352(6282):189-196. doi:10.1126/science.aad0501 PMID: 27124452
90. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nature Reviews Immunology. 2015;15(7):405-414. doi:10.1038/nri3845 PMID: 26027717
91. Fischer A, VaAzquez-GarcoAa I, Illingworth CJ, Mustonen V. High-definition reconstruction of clonal composition in cancer. Cell reports. 2014;7(5):1740-1752. doi:10.1016/j.celrep. 2014.04.055 PMID: 24882004
92. Roth A, Khattra J, Yap D, Wan A, Laks E, Biele J, et al. PyClone: statistical inference of clonal population structure in cancer. Nature methods. 2014;.
93. Zare H, Wang J, Hu A, Weber K, Smith J, Nickerson D, et al. Inferring clonal composition from multiple sections of a breast cancer. PLoS computational biology. 2014;10(7):e1003703. doi:10.1371/journal. pcbi.1003703 PMID: 25010360
94. Schuh A, Becq J, Humphray S, Alexa A, Burns A, Clifford R, et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood. 2012;120(20):4191-4196. doi:10.1182/blood-2012-05-433540 PMID: 22915640
95. Marass F, Mouliere F, Yuan K, Rosenfeld N, Markowetz F. A phylogenetic latent feature model for clonal deconvolution. arXiv preprint arXiv:160401715. 2016;.
96. Matsui Y, Niida A, Uchi R, Mimori K, Miyano S, Shimamura T. phyC: Clustering cancer evolutionary trees. bioRxiv. 2016; p. 069302.
97. Jiang Y, Qiu Y, Minn AJ, Zhang NR. Assessing intratumor heterogeneity and tracking longitudinal and spatial clonal evolutionary history by next-generation sequencing. Proceedings of the National Academy of Sciences. 2016;113(37):E5528-E5537. doi:10.1073/pnas.1522203113
98. Newman AM, Alizadeh AA. High-throughput genomic profiling of tumor-infiltrating leukocytes. Current Opinion in Immunology. 2016;41:77-84. doi:10.1016/j.coi.2016.06.006 PMID: 27372732
99. Gaujoux R, Seoighe C. CellMix: a comprehensive toolbox for gene expression deconvolution. Bioinformatics. 2013;29(17):2211-2212. doi:10.1093/bioinformatics/btt351 PMID: 23825367
100. Chikina M, Zaslavsky E, Sealfon SC. CellCODE: a robust latent variable approach to differential expression analysis for heterogeneous cell populations. Bioinformatics. 2015; p. btv015. doi:10.1093/bioinformatics/btv015
101. Houseman EA, Kile ML, Christiani DC, Ince TA, Kelsey KT, Marsit CJ. Reference-free deconvolution of DNA methylation data and mediation by cell composition effects. bioRxiv. 2016; p. 037671.
102. Hastie T, Tibshirani R, Eisen MB, Alizadeh A, Levy R, Staudt L, et al. Gene shaving as a method for identifying distinct sets of genes with similar expression patterns. Genome Biol. 2000;1(2):1-0003. doi:10.1186/gb-2000-1-2-research0003